ArticleFrontiers in immunology2026
Harnessing SARS-CoV-2 immunity to promote antitumor responses through intratumoral vaccination and adoptive transfer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cancer immunotherapy holds promise for the treatment of malignancies by mobilizing the immune system; however, its efficacy remains limited in tumors that lack immune infiltration. Innovative approaches are therefore required to convert these immunologically "cold" tumors into "hot" tumors that are more susceptible to immune-mediated attack. Therapeutic vaccination represents one such strategy, capable of triggering robust immune activation and durable memory responses. Given that the vast majority of the global population has either been vaccinated against or exposed to SARS-CoV-2, we hypothesized that pre-existing antiviral immunity could be locally leveraged to enhance intratumoral immune responses. Methods: To test this concept, we evaluated the therapeutic efficacy of intratumoral SARS-CoV-2 vaccination in the B16F10 murine melanoma model using two SARS-CoV-2 vaccine platforms: pVAX-SARS-S, a DNA vaccine encoding the spike protein S1 subunit and rAd-SARS2-S1/CD40L, a recombinant adenovirus expressing a secreted S1-CD40L fusion protein. Tumor-bearing C57BL/6 mice were treated intratumorally with either vaccine in the presence or absence of prior immunization, which had been established six months earlier to mimic pre-existing antiviral immunity. Results: Intratumoral vaccination with pVAX-SARS-S significantly reduced tumor burden and prolonged survival in both naïve and pre-immunized mice. Its antitumor protection could be adoptively transferred via splenocytes, indicating the involvement of systemic adaptive immunity in mediating tumor rejection. The rAd-SARS2-S1/CD40L platform conferred modest tumor control. While both vaccines were effective, the DNA platform demonstrated superior efficacy. Discussion: Together, these findings provide proof-of-concept that intratumoral administration of SARS-CoV-2 vaccines can promote antitumor effects through local immune activation in the context of pre-existing antiviral immunity. This strategy may offer a translatable approach for enhancing intratumoral immunotherapy in the post-pandemic era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.